"The conceptualization of this study was based on its Phase 2 trials (graphically summarized below), where apabetalone, in conjunction with the standard of care (ie a statin) showed significant reduction in MACE, especially in those patients with DM. Specifically, their analysis revealed a 57% relative risk reduction in the incidence of MACE in CVD with DM."

FYI, not a misprint. The 77% RRR that we've seen before was from the pooled ASSURE/SUSTAIN. This 57% number is from the recently published study that pooled ASSERT/SUSTAIN/ASSURE data.